PHC and JCR Pharmaceuticals Jointly Develop and Launch Sales of Electric Injector 'Growject Duo' Exclusively for Human Growth Hormone Preparation 'Growject'

Aug 17, 2023

PHC Corporation Diagnostics Division (Headquarters: Minato-ku, Tokyo, President: Shinro Nakamura, hereinafter 'PHC IVD') and JCR Pharma Corporation (Headquarters: Ashiya City, Hyogo Prefecture, Chairman and President: Makoto Ashida), hereinafter referred to as 'JCR Pharma') is pleased to announce the launch of 'Growjector Duo (1)' as a new treatment option for the electric growth hormone injection device 'Growjector' series, which was launched in 2006.

It will be jointly developed and JCR Pharma will start selling it from September 1st.

'Growjector Duo' manufactured by PHC IVD is an electronic pharmaceutical injector exclusively for the recombinant natural human growth hormone 'Growject Subcutaneous Injection 6mg and 12mg (2)' manufactured and sold by JCR Pharmaceuticals. This product was developed for users who prefer simpler operation, based on the treatment status and market needs of conventional products. 'Growjector Duo' has a simple appearance and operability, but also reduces the burden of injection by automatic injection and automatically records injection history.

With the launch of 'Growjector Duo', the product lineup of the Glowjector series has been further expanded. 'Growjector L (3)', which has a full range of support functions, is suitable for injections for young children, and 'Growjector Duo', which pursues the ease of use of a pen-type injector, is suitable for elderly children . In addition to being suitable for injections, it is also suitable for injections by parents who require simple functions and operations. The Growjector series expands the patient's options for various treatment opportunities and supports long-term treatment.

PHC IVD and JCR Pharma will provide healthcare solutions that meet the needs of everyone involved in growth hormone therapy, helping to improve the QOL of patients and aiming to realize higher quality medical care.

About PHC Corporation Diagnostics Division

PHC Corporation, established in 1969, develops, manufactures, sells, and services in the business areas of diabetes management, diagnostics, and life sciences, and operates as a global healthcare company. Tokyo Stock Exchange Prime) operating subsidiary in Japan. Based on our management philosophy of creating new value for all people who desire good health and contributing to the creation of a prosperous society, the Diagnostics Division develops, manufactures, and sells blood glucose measurement systems and other testing and analysis equipment. Through these efforts, we are contributing to the early detection and effective treatment of diseases such as diabetes and asthma, and are working to improve medical services for patients.

About JCR Pharmaceuticals Co., Ltd.

Based on our corporate philosophy of 'contributing to people's health through pharmaceuticals,' we are a biopharmaceutical company that researches and develops, manufactures, and sells pharmaceuticals using cutting-edge regenerative medicine, genetic recombination, and gene therapy technologies. We are a specialty pharma. Since our founding in 1975, we have been targeting rare diseases, and we are constantly working to develop unique technologies and create products that are one step ahead of other companies, and to create sustainable value for patients suffering from various diseases. We are aiming for realization.

Contact:

Tel: 070-1449-9486

Email: [email protected]

(C) 2023 Electronic News Publishing, source ENP Newswire